Generated by All in One SEO v4.9.7.2, this is an llms.txt file, used by LLMs to index the site. # Renbio RenBio is a biotechnology company based in the heart of New York City, founded by the desire to revolutionize antibody-based prevention and treatment of diseases. ## Sitemaps - [XML Sitemap](https://www.renbio.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Pages - [Home](https://www.renbio.com/) - Observe the efficacy of antibodies therapeutic in reducing the impact of diseases. Get to know our Make Your Own Technology™ and behold the future of medicine. - [MYO Applications](https://www.renbio.com/myo-applications/) - The flexibilityto go further The flexibility to go further. Protein therapeutic treatments have another life and can be applicated in blood disorders, inflammatory diseases or viral infections. - [MYO Technology](https://www.renbio.com/myo-technology/) - Changing the Therapeutic and the Treatment Landscape We are changing antibody and therapeutic protein delivery. We empower patients to produce their own medicines: get to know our Make Your Own Technology™. - [Contact us](https://www.renbio.com/contact/) - We are delighted that you have visited this page to connect with us. If you wish to learn more about our MYO Technology™ platform or our company, please feel free to contact us via email at: info@renbio.com. To stay updated on the latest news from RenBio, please follow us on LinkedIn. Do you know we are working on delivering next-generation medicines? Contact us to know more and visit our LinkedIn and Twitter to meet the future of medicine. - [Financial Conflict of Interest Policy](https://www.renbio.com/financial-conflict-of-interest-policy/) - Check our Financial Conflict of Interest Policy for Promoting Objectivity in Research here. ## News & Events - [RenBio Highlights Potential of DNA-Based GLP-1 Therapies for Durable Weight Loss](https://www.renbio.com/news_and_events/renbio-highlights-potential-of-dna-based-glp-1-therapies-for-durable-weight-loss/) - RenBio’s latest publication highlights the potential of DNA-based medicines for metabolic disease. In a study published in Molecular Therapy Nucleic Acids, RenBio demonstrated that delivery of ultra long-lasting GLP-1-based incretin receptor agonists using its proprietary MYO Technology™ led to sustained weight loss for up to one year from a single administration in a diet-induced obesity model. - [RenBio’s Dr. Rachel Liberatore Presents at ASGCT Annual Meeting in Boston](https://www.renbio.com/news_and_events/renbios-dr-rachel-liberatore-presents-at-asgct-annual-meeting-in-boston/) - On May 12, RenBio’s President and Chief Scientific Officer, Dr. Rachel Libertore attended the ASGCT 2026 Annual Meeting in Boston, where she presented a poster on DNA-based delivery of broadly neutralizing antibody cocktails as a universal influenza vaccine alternative (Abstract 1101). It was an honor to share the Company’s work on ultra long-lasting DNA medicines - [Exciting progress in the fight against obesity](https://www.renbio.com/news_and_events/exciting-progress-in-the-fight-against-obesity/) - Exciting progress in the fight against obesity: researchers are exploring DNA-based approaches that could turn cells into long-term producers of GLP-1. At RenBio, we’re advancing next-generation gene delivery technologies that make such innovations possible. Learn more in CNN’s recent article on this breakthrough: https://www.cnn.com/2025/11/04/health/obesity-glp1-gene-therapy-research - [RenBio is excited to provide an update on our ultra long-acting GLP-1 receptor agonist program.](https://www.renbio.com/news_and_events/renbio-is-excited-to-provide-an-update-on-our-ultra-long-acting-glp-1-receptor-agonist-program/) - Using our proprietary, DNA-based MYO Technology delivery platform, we are able to achieve >1 year of sustained weight loss in a diet-induced obesity model from a single administration. Please reach out to us to learn more! We'll also be at the Biotech Showcase during JPM week in San Francisco this January. - [RenBio Announces New Awards to Support Continued Development of Its Novel, DNA-Based MYO TechnologyTM Platform for Antiviral Applications](https://www.renbio.com/news_and_events/renbio-announces-new-awards-to-support-continued-development-of-its-novel-dna-based-myo-technologytm-platform-for-antiviral-applications/) - $2.9 Million Received From Wellcome for DNA-Based Delivery of Antiviral Antibodies for Zika and Influenza Prevention, Focusing on Preclinical Development of a Potent Anti-Zika Antibody and Optimizing Antibody Cocktail Delivery $749,000 Contract from the BARDA Flexible and Strategic Therapeutics (FASTx) Program for DNA-Based Delivery of Anti Influenza Antibodies to Large Animals, With an Emphasis on - [ASGCT 27th Annual Meeting in Baltimore](https://www.renbio.com/news_and_events/asgct-27th-annual-meeting-in-baltimore/) - Last week, RenBio's Dr. Rachel Liberatore and Dr. Linda Sasset attended the ASGCT 27th Annual Meeting in Baltimore. It was an honor to be in attendance, where we connected with fellow innovators and leaders in the field of gene and cell therapy. Dr. Sasset's abstract, titled "Next-Generation DNA-Based Delivery of Therapeutic Proteins Using MYO Technology: - [RenBio at BIO CEO & Investor Conference](https://www.renbio.com/news_and_events/renbio-at-bio-ceo-investor-conference/) - Dr. Rachel Liberatore had the privilege of representing RenBio last week at the BIO CEO & Investor Conference held in New York. Dr. Liberatore showcased our groundbreaking work in the biotech industry to an audience of leaders and investors. The BIO CEO & Investor Conference provided a platform for RenBio to spotlight our innovative projects - [RenBio at AntibodyTherapeutics Xchange 2024](https://www.renbio.com/news_and_events/renbio-at-antibodytherapeutics-xchange-2024/) - RenBio's Dr. Rachel Liberatore took center stage at the AntibodyTherapeutics Xchange 2024 event held in Philadelphia this week. Dr. Liberatore led a captivating round table discussion on "Novel Delivery Modes for Biologics". The discussion was a dynamic exploration of strategies aimed at enhancing pharmacokinetics, tackling the challenges of cold chain requirements, and alleviating the burden - [AI in Action E413: Rachel Liberatore, President & Chief Scientific Officer at RenBio](https://www.renbio.com/news_and_events/ai-in-action-e413-rachel-liberatore-president-chief-scientific-officer-at-renbio/) - We're thrilled to share that Dr. Rachel Liberatore, our President & Chief Scientific Officer, joined JP Valentine on the "AI in Action '' podcast to discuss RenBio's groundbreaking work. In this episode, Dr. Liberatore dives into RenBio's MYO technology. Listen as Dr. Liberatore shares her expertise and insights on RenBio's interdisciplinary approach, collaboration with DARPA's - [Renbio at Biotech Showcase](https://www.renbio.com/news_and_events/renbio-at-biotech-showcase/) - Discover biotech breakthroughs with Dr. Rachel Liberatore at the SF Showcase. Missed it? Connect for collaborations, insights into MYO Technology, and RenBio's vision. - [RenBio's Highlight at the Life Sciences Summit: A Showcase of Innovation](https://www.renbio.com/news_and_events/renbios-highlight-at-the-life-sciences-summit-a-showcase-of-innovation/) - We're excited to share the fantastic news of our recent participation in the Life Sciences Summit at the Alexandria Center for Life Science! The Life Sciences Summit provided a unique platform for RenBio to shine, and we're thrilled to announce that our very own Dr. Rachel Liberatore, PhD, was selected to present at the emerging - [RenBio Attends New York BIO Annual Meeting](https://www.renbio.com/news_and_events/renbio-attends-new-york-bio-annual-meeting/) - RenBio is excited to share that our very own Rachel Liberatore, Chief Scientific Officer, had the privilege of attending New York BIO Annual Meeting last month. This event marked a significant gathering of key players in the biotechnology and life sciences industry. The New York BIO Annual Meeting is a renowned event that brings together - [RenBio's Rachel Liberatore to Present at Vaccines Summit 2023](https://www.renbio.com/news_and_events/renbios-rachel-liberatore-to-present-at-vaccines-summit-2023/) - We are excited to announce that RenBio's Dr. Rachel A. Liberatore will be attending and presenting at the upcoming Vaccines Summit 2023 in Boston, scheduled for November 13-15. Her presentation, titled "DNA-based delivery of antiviral antibodies for infectious disease prevention," promises to shed light on innovative approaches to enhance our battle against infectious diseases. Presentation - [RenBio attends the Keystone Symposia](https://www.renbio.com/news_and_events/renbio-attends-the-keystone-symposia-on-next-generation-antibody-therapeutics-from-discovery-to-patient/) - RenBio had the pleasure of attending the Keystone Symposia on “Next Generation Antibody Therapeutics: From Discovery to Patient” last month. Our Director of Research, Marek Drozdz, Ph.D., presented a poster showcasing the potential of RenBio’s MYO Technology™ to deliver antibodies and therapeutic proteins in a way that is durable and efficacious. The attendees met this - [RenBio's Rachel Liberatore at LSX - Partnering for Life Science Executives in Boston](https://www.renbio.com/news_and_events/renbios-rachel-liberatore-at-lsx-partnering-for-life-science-executives-in-boston/) - Earlier this month Our President and Chief Scientific Officer, Dr. Rachel Liberatore represented RenBio at the LSX - Partnering for Life Science Executives event in Boston. This annual conference brings together key players in the life science industry, providing a unique platform for collaboration, networking, and learning. Dr Liberatore had the opportunity to engage in - [RenBio featured in Nature OUTLOOK: The genetic shortcut to antibody drugs](https://www.renbio.com/news_and_events/renbio-featured-in-nature-outlook-the-genetic-shortcut-to-antibody-drugs/) - Insertion of genetic information can prompt the body to make antibody-based drugs, offering a fresh approach to treating diseases such as influenza, as well as infections like HIV. Lear more here: https://www.nature.com/articles/d41586-018-07645-x - [RenBio’s COO, Neal Padte, presents on “Antibody Gene Transfer by In Vivo Electroporation” at the "3rd World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies." ](https://www.renbio.com/news_and_events/renbios-coo-neal-padte-presents-on-antibody-gene-transfer-by-in-vivo-electroporation-at-the-3rd-world-congress-on-electroporation-and-pulsed-electric-fields-in/) - Learn more here: https://wc2019.electroporation.net/ - [RenBio's DARPA-Funded Tech Spotlighted at Meeting](https://www.renbio.com/news_and_events/renbios-darpa-funded-immunity-on-demand-technology-highlighted-at-biotech-startups-of-the-future-meeting/) - DARPA has enjoyed a strong relationship with Silicon Valley since the early 1960s, working with innovators to lay the groundwork for new industries built around Agency investments in semiconductors, networking, artificial intelligence, user interfaces, programming, materials, microsystems, and more. Biotech is now emerging as a breakthrough opportunity space and it represents an area that is - [RenBio Scientists Review DNA Antiviral Delivery](https://www.renbio.com/news_and_events/renbio-scientists-and-co-founders-review-the-state-of-dna-based-antiviral-antibody-delivery-particularly-for-the-prevention-of-infectious-disease/) - With increasing frequency, humans are facing outbreaks of emerging infectious diseases (EIDs) with the potential to cause significant morbidity and mortality. In the most extreme instances, such outbreaks can become pandemics, as we are now witnessing with COVID-19. Our scientists Chasity D. Andrews and Rachel A. Liberatore, PhD and our co-founders YaoXing Huang, PhD and - [RenBio with Global Rights for COVID-19 Bispecific Antibody](https://www.renbio.com/news_and_events/renbio-completes-24m-series-a-financing/) - RenBio, a private preclinical biotech firm, completed a $24M Series A financing led by Ruentex Group from Taiwan. We focus on novel antiviral antibody therapeutics and an advanced antibody delivery platform. RenBio has also signed a license agreement with Columbia University, giving our company the exclusive worldwide development and commercialization rights to a novel bispecific - [RenBio participates in NIH Summit](https://www.renbio.com/news_and_events/renbios-director-of-rd-rachel-liberatore-participates-as-panelist-in-nih-summit-on-anti-sars-cov-2-antibodies/) - Our Director of R&D, Rachel Liberatore, PhD, participated as a panelist in NIH Summit on "Anti-SARS-CoV-2 Antibodies for Treatment and Prevention of COVID-19: Lessons Learned and Remaining Questions". One of this summit's goal is to summarize current knowledge and lessons learned on clinically relevant anti-SARS-CoV-2 antibodies for the treatment and/or prevention of COVID-19. Identify key - [RenBio's New Address](https://www.renbio.com/news_and_events/biotech-company-renbio-moves-to-7k-sf-in-long-island-city/) - Private biotechnology company RenBio is moving its offices to Alexandria Real Estate Equities’ 30-02 48th Avenue in Long Island City, Queens. The firm relocated in mid-June from another Alexandria property at 430 East 29th Street in Manhattan, according to a representative from CBRE, who brokered the deal for the tenant. The representative would not disclose - [RenBio Secures Grants for DNA Therapeutics](https://www.renbio.com/news_and_events/renbio-announces-the-award-of-two-grants-to-support-continued-development-of-its-novel-dna-therapeutics-myo-technology-platform-for-infectious-disease-applications/) - $2.0 Million Grant from the New York State Biodefense Commercialization Fund Approximately $1.0 Million Received as Sub-Awardee of Vanderbilt University Under DARPA’s Pandemic Prevention Platform (P3) Program RenBio, our private preclinical biotech firm, announced significant funding milestones today. We have secured a $2.0 million grant from Empire State Development's New York State Biodefense Commercialization Fund - [Nucleic Acid Antibody Delivery: BioWorld Review](https://www.renbio.com/news_and_events/bioworld-reviews-the-nucleic-acid-based-antibody-delivery-field-including-renbios-myo-technology-2/) - Monoclonal antibodies are a triumph of modern medicine. They are also too expensive to be a standard therapy in all but the wealthiest countries. “Having 10% or 15% of your population on antibodies is not sustainable even in wealthy countries,” Rachel Liberatore told BioWorld. Liberatore is director of research and development at Renbio Inc., which - [RenBio presents at World Congress on Electroporation](https://www.renbio.com/news_and_events/renbio-presents-at-international-electroporation-conference/) - RenBio’s Andrew Cameron presented at this year’s World Congress on Electroporation and Pulsed Electric Fields on the MYO Technology™ platform for monoclonal antibody delivery. The World Congress is sponsored by the International Society for Electroporation-Based Technologies and Treatments. The congress showcased scientific advancement through compelling plenary talks, four daily parallel scientific sessions, and poster presentations. - [RenBio to attend BIO International Convention in Boston](https://www.renbio.com/news_and_events/renbio-to-attend-bio-in-boston-5-8-june/) - Text: Our President and Chief Scientific Officer, Dr. Rachel Liberatore, will be attending the BIO International Convention in Boston on 5-8 June. At BIO, Rachel is eager to connect with potential partners interested in utilizing the MYO Technology™ platform for developing innovative DNA delivery methods for therapeutic antibodies and proteins. Rachel will also be delighted - [RenBio attended BIO International Convention](https://www.renbio.com/news_and_events/renbio-attended-bio-international-convention/) - Our President and Chief Scientific Officer, Dr. Rachel Liberatore, attended the BIO International Convention in Boston last month. The event was a success, providing RenBio with valuable networking opportunities. Our revolutionary MYO Technology™ platform received a fervent response. Dr. Liberatore had a great week engaging with a diverse array of potential collaborators and industry experts. ## Team - [Marek M. Drozdz, Ph.D.](https://www.renbio.com/team/marek-m-drozdz-ph-d/) - Dr. Drozdz has over 10 years of experience studying cellular signaling in both normal and disease states. - [Rachel A. Liberatore, Ph.D.](https://www.renbio.com/team/rachel-a-liberatore/) - Dr. Liberatore has extensive experience developing and directing discovery and proof-of-concept studies using multiple models of human diseases. Her previous work in the Laboratory of Retrovirology at the Aaron Diamond AIDS Research Center was aimed at understanding viral pathogenesis, with a particular focus on interferon-mediated antiviral responses and elicitation of antiviral antibodies. At RenBio, Dr. - [Angelo Del Parigi](https://www.renbio.com/team/angelo-del-parigi/) - [Walter Wang Jr.](https://www.renbio.com/team/walter-wang-jr/) - [Zhi Hong, PhD](https://www.renbio.com/team/zhi-hong-phd/) - [Jaap Goudsmit, MD, PhD](https://www.renbio.com/team/jaap-goudsmit-md-phd/) - [Donald Tang, CFA](https://www.renbio.com/team/donald-tang-cfa/) - [Carleigh Sussman](https://www.renbio.com/team/carleigh-sussman/) - Ms. Sussman received her Bachelor of Science degree in Biology from Northeastern University. Between her experiences at Northeastern and her position as a Research Technician at Memorial Sloan Kettering Cancer Center, Ms. Sussman has over four years of experience in the field utilizing both in vitro and in vivo model systems. She is skilled in - [Annelyn P. O’Rourke, CPA](https://www.renbio.com/team/annelyn-p-orourke/) - Ms. O’Rourke has over 20 years of experience in various accounting functions for healthcare and biotechnology companies, previously serving as Controller for the Amsterdam Nursing Home and an Auditor for Empire Blue Cross Blue Shield. Ms. O’Rourke received her Bachelor of Science in Accounting from Queens College and passed the NYS Public Accountancy exam. - [Debnath Maji, Ph.D.](https://www.renbio.com/team/debnath-maji-ph-d/) - Dr. Debnath Maji is a research engineer and an academic specializing in biomedical engineering with an extensive background in the development of diagnostic and therapeutic medical devices. Currently, he serves as an Assistant Professor at Louisiana State University in the Department of Biological and Agricultural Engineering, where he leads the Emerging Diagnostics and Innovative Therapeutics - [Thanos Papaïoannou, Ph.D.](https://www.renbio.com/team/thanos-papaioannou/) - Thanos Papaïoannou has led $450m+ of investments in machine learning and physics-based technologies at Roivant Sciences (NASDAQ: ROIV), a $5b+ biopharma and technology company with a pipeline of 45+ investigational drugs across 14 therapeutic areas. Before joining Roivant, Thanos worked in quantitative strategy portfolio management at Ellington Management Group, a multi-billion dollar hedge fund. He - [Yaoxing Huang, Ph.D.](https://www.renbio.com/team/yaoxing-huang-phd/) - Dr. Huang is currently an Associate Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons. - [Jim Ackland](https://www.renbio.com/team/jim-ackland/) - Mr. Ackland has more than 45 years of experience in manufacturing, quality control, development, and international regulatory requirements for vaccine and biopharmaceutical products. He is currently Managing Director and Chief Executive Officer of Australia-based Global BioSolutions, providing regulatory and product development advice and assistance to biotechnology companies globally, including in the area of vaccine development. - [Martin Markowitz, M.D.](https://www.renbio.com/team/martin-markowitz-m-d/) - Dr. Markowitz is currently a Special Lecturer in the Department of Medicine and Infectious Diseases at Columbia University Irving Medical Center. In his previous position at the Aaron Diamond AIDS Research Center (ADARC), he served as the Clinical Director and Principal Investigator on approximately 80 clinical trials, both investigator-initiated and multisite studies sponsored by industry - [David D. Ho, MD](https://www.renbio.com/team/david-d-ho-md/) - Dr. Ho is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons. ## Categories - [Team](https://www.renbio.com/category/team/) - [co-founders](https://www.renbio.com/category/co-founders/) - [Partners](https://www.renbio.com/category/partners/) - [Directors](https://www.renbio.com/category/directors/)